MARCH – APRIL 2024 Shooting Cancer Highlights: Periodic focus on regulatory status of new targeted therapies in oncology
EMA April 23 – Tislelizumab – NSCLC EGFR/ALK. The European Commission (EC) has approved the anti-PD-1 monoclonal antibody, across 3 indications for the first- and second-line treatment of adult patients with non–small cell lung cancer (NSCLC). In particular, tislelizumab, in combination with pemetrexed and platinum?containing chemotherapy, is indicated for the first-line treatment of adult patients […]